Table 2.
Bivariate and multivariate analysis of factors associated with any alcohol use compared to none (n = 922, analyses adjusted for site)
| Variable | Bivariate OR (95% CI) | Multivariate OR (95% CI) |
|---|---|---|
| Sex | ||
| Female | 1.0 (Ref) | 1.0 (Ref) |
| Male | 2.01 (1.46–2.75)* | 1.52 (1.07–2.16)* |
| Age | ||
| 18–34 | 1.0 (Ref) | 1.0 (Ref) |
| 35–44 | 0.98 (0.59–1.62) | 1.02 (0.58–1.79) |
| ≥45 | 0.72 (0.44–1.19)** | 0.79 (0.45–1.39) |
| Race/ethnicity | ||
| White | 1.0 (Ref) | 1.0 (Ref) |
| African American | 0.84 (0.58–1.20) | 1.05 (0.71–1.57) |
| Hispanic | 0.66 (0.40–1.09)** | 0.77 (0.45–1.33) |
| Other | 0.75 (0.34–1.65) | 0.72 (0.31–2.68) |
| Education | ||
| < High school degree | 1.0 (Ref) | 1.0 (Ref) |
| High school or junior college | 1.45 (1.03–2.03)* | 1.25 (0.87–1.81) |
| College or post-college | 1.97 (1.23–3.17)* | 1.87 (1.10–3.18)* |
| Insurance | ||
| Private | 1.0 (Ref) | 1.0 (Ref) |
| Medicaid | 0.47 (0.30–0.73)* | 0.58 (0.36–0.96)* |
| Medicare | 1.16 (0.66–1.98) | 1.30 (0.72–2.32) |
| Medicaid/Medicare | 0.61 (0.38–0.97)* | 0.71 (0.42–1.18) |
| None | 1.55 (0.89–2.70)** | 1.84 (1.00–3.40) |
| HAART | ||
| No | 1.0 (Ref) | 1.0 (Ref) |
| Yes | 1.47 (1.08–1.99)* | 1.62 (1.15–2.29)* |
| CD4 nadir (cells/μL) | ||
| < 50 | 1.0 (Ref) | 1.0 (Ref) |
| 50–199 | 1.08 (0.74–1.56) | 1.12 (0.75–1.68) |
| 200–499 | 0.82 (0.57–1.19) | 1.02 (0.68–1.54) |
| ≥ 500 | 1.41 (0.86–2.32)** | 1.64 (0.94–2.87) |
| Missing | 1.00 (0.49–2.03) | 1.24 (0.56–2.71) |
| Illicit drug use | ||
| Never | 1.0 (Ref) | 1.0 (Ref) |
| Former | 0.80 (0.56–1.17) | 0.87 (0.59–1.28) |
| Current | 2.34 (1.65–3.31)* | 2.69 (1.82–3.95)* |
| Outpatient psychiatric treatment | ||
| No | 1.0 (Ref) | 1.0 (Ref) |
| Yes | 0.77 (0.57–1.04)** | 0.77 (0.55–1.07) |
| Primary care visits | ||
| ≤ 3 visits | 1.0 (Ref) | 1.0 (Ref) |
| 4–5 visits | 0.69 (0.44–1.09)** | 0.65 (0.40–1.05) |
| 6–7 visits | 0.89 (0.61–1.29) | 1.05 (0.70–1.58) |
| ≥ 8 visits | 0.49 (0.33–0.71)* | 0.51 (0.35–0.78)* |
CI, confidence interval; HAART, highly active antiretroviral therapy.
P < 0.05.
P < 0.20.